Table 4.
Results of Scenario Analyses.
| Comparator 4 | Comparator 5 | Comparator 6 | Comparator 7 | Comparator 8 | |
|---|---|---|---|---|---|
| Regimen | PEP | PEP | PEP | PEP | PEP |
| Route of administration | ID | ID | IM | IM | IM |
| Scenario 1 (Local Wound Infilteration of ERIG) | |||||
| Quasi-Societal Perspective | |||||
| ICER (INR/DALYs averted) | −7267.82 | −7123.51 | −7003.76 | −6673.78 | −6669.53 |
| ICER (USD/DALYs averted) | −383.97 | −376.35 | −370.02 | −352.59 | −352.36 |
| Quasi-Health Systems’ Perspective | |||||
| ICER (INR/DALYs averted) | −2543.45 | −2492.97 | −2448.61 | −2333.14 | −2331.21 |
| ICER (USD/DALYs averted) | −134.37 | −131.71 | −129.36 | −123.26 | −123.16 |
| Scenario 2 (Use of HRIG) | |||||
| Quasi-Societal Perspective | |||||
| ICER (INR/DALYs averted) | −6634.01 | −6534.25 | −6448.3 | −6219.27 | −6215.31 |
| ICER (USD/DALYs averted) | −350.49 | −345.22 | −340.67 | −328.58 | −328.37 |
| Quasi-Health Systems’ Perspective | |||||
| ICER (INR/DALYs averted) | −2321.54 | −2286.67 | −2254.33 | −2174.17 | −2172.38 |
| ICER (USD/DALYs averted) | −122.65 | −120.81 | −119.1 | −114.87 | −114.77 |
| Scenario 3 (Use of R-Mab) | |||||
| Quasi-Societal Perspective | |||||
| ICER (INR/DALYs averted) | −6418.01 | −6331.89 | −6258.23 | −6058.01 | −6054.14 |
| ICER (USD/DALYs averted) | −339.08 | −334.53 | 330.63 | −320.06 | −319.85 |
| Quasi-Health Systems’ Perspective | |||||
| ICER (INR/DALYs averted) | −2245.97 | −2215.87 | −2187.9 | −2117.82 | −2116.07 |
| ICER (USD/DALYs averted) | −118.66 | −117.07 | −115.59 | −111.89 | −111.8 |
DALY = disability-adjusted life years; ERIG = equine rabies immunoglobulin; HRIG = human rabies immunoglobulin; ICER = incremental cost-effectiveness ratio; INR = Indian national rupee; QALY = quality-adjusted life years; R-Mab = rabies monoclonal antibodies; USD = US dollars.